Editor's Choice
What's your price?
BMJ 2003; 327 doi: https://doi.org/10.1136/bmj.327.7410.0-g (Published 07 August 2003) Cite this as: BMJ 2003;327:0-gRelated articles
- Review Published: 07 August 2003; BMJ 327 doi:10.1136/bmj.327.7410.348-a
- Letter Published: 07 August 2003; BMJ 327 doi:10.1136/bmj.327.7410.341-a
- Letter Published: 07 August 2003; BMJ 327 doi:10.1136/bmj.327.7410.341-b
- Letter Published: 07 August 2003; BMJ 327 doi:10.1136/bmj.327.7410.342
- Letter Published: 07 August 2003; BMJ 327 doi:10.1136/bmj.327.7410.342-b
- Letter Published: 07 August 2003; BMJ 327 doi:10.1136/bmj.327.7410.342-a
- Letter Published: 07 August 2003; BMJ 327 doi:10.1136/bmj.327.7410.342-c
See more
- Indonesian doctors risk losing licence if they castrate paedophilesBMJ October 25, 2016, 355 i5762; DOI: https://doi.org/10.1136/bmj.i5762
- Anabolic steroid useBMJ October 13, 2016, 355 i5023; DOI: https://doi.org/10.1136/bmj.i5023
- Testosterone supplementation for “low T” is not supported by evidence, review concludesBMJ September 22, 2016, 354 i5166; DOI: https://doi.org/10.1136/bmj.i5166
- Risk of erectile dysfunction associated with use of 5-α reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research DatalinkBMJ September 22, 2016, 354 i4823; DOI: https://doi.org/10.1136/bmj.i4823
- Approved drugs are to be studied for use in Alzheimer’s diseaseBMJ September 19, 2016, 354 i5063; DOI: https://doi.org/10.1136/bmj.i5063